Beyond the GLP-1 Duopoly: Three October Developments That Signal a Broadening Obesity Pipeline

Key takeaways

• Zealand Pharma's amylin analogue petrelintide achieved up to 9.2% mean body weight reduction at week 28 in the Phase 2b ZUPREME-2 trial, with a tolerability profile comparable to placebo.
• One week later, Zealand struck a collaboration with Generate Biomedicines worth up to USD 1.2 billion to design AI-engineered multispecific protein therapeutics for obesity — a modality shift away from pure peptide approaches.
• Novo Nordisk separately licensed Nanexa's PharmaShell atomic layer deposition delivery platform for up to five peptide programmes in a deal valued at up to €1.165 billion, targeting monthly and quarterly injection frequencies.
• Taken together, these three October 2026 developments reflect an industry-wide effort to differentiate from weekly subcutaneous GLP-1 injections on the dimensions of mechanism, dosing convenience, and tolerability.
• For UK research procurement teams, the broadening pipeline increases the range of reference compounds and analytical standards likely to be required over the next 24–36 months.

The GLP-1 receptor agonist class — dominated commercially by Novo Nordisk's semaglutide and Eli Lilly's tirzepatide — has defined obesity pharmacotherapy since the early 2020s. Yet the first three weeks of October 2026 produced three deal announcements that, read together, suggest the next competitive battleground will be fought on different terms: alternative peptide mechanisms, engineered multispecific proteins, and formulation technologies that extend injection intervals from weekly to monthly or quarterly.

Petrelintide: An Amylin Analogue With Phase 2b Evidence

On 7 October 2026, Zealand Pharma reported topline results from ZUPREME-2, a Phase 2b randomised controlled trial of petrelintide in 220 adults with overweight or obesity and type 2 diabetes. The trial met its primary endpoint: once-weekly subcutaneous petrelintide produced statistically significant and clinically meaningful body weight reductions, with participants achieving up to 9.2% mean weight loss from baseline at week 28 (range across treatment arms: 7.4–9.2%) versus 2.0% with placebo.

The drug also demonstrated an HbA1c reduction of up to 0.65% at week 28 versus an increase of 0.23% with placebo. The glycaemic signal is of relevance to research groups investigating dual metabolic endpoints in cardiometabolic models.

Petrelintide is a long-acting human amylin analogue designed for once-weekly subcutaneous administration, with chemical and physical stability and no fibrillation around neutral pH — a property intended to allow co-formulation and co-administration with other peptides. The hormone amylin is produced in the pancreatic beta cells and co-secreted with insulin in response to ingested nutrients, making it a mechanistically distinct counterpart to the incretin axis targeted by GLP-1 agonists.

Tolerability data were favourable. Gastrointestinal side effects were mostly mild and occurred mainly during dose escalation, with very low discontinuation rates — 1.9% for petrelintide versus 1.7% on placebo. The profile is notable because gastrointestinal burden has been one of the principal attrition drivers in the GLP-1 class.

The ZUPREME-2 data reinforce findings from ZUPREME-1 and support an ongoing Phase 3 programme (ZUPREME-3, 4, and 5, with approximately 7,000 participants) that has already begun enrolling, testing petrelintide alone and in combination with Roche's dual GLP-1/GIP agonist enicepatide. Zealand is jointly developing petrelintide with Roche under an agreement worth up to USD 5.3 billion signed in 2025.

Investigators and procurement professionals should note that these remain topline findings; the complete ZUPREME-2 dataset, including the full analysis of prespecified outcomes, has not yet been presented. Full data presentation at a scientific congress will be required before the mechanistic details relevant to translational research can be comprehensively assessed.

Zealand and Generate: AI-Designed Proteins Enter the Obesity Race

Six days after the petrelintide data readout, Zealand took a different strategic step. On 13 October 2026, Generate Biomedicines and Zealand Pharma announced a multi-target collaboration and licence agreement to design and develop multispecific protein therapeutics — medicines engineered to act on more than one biological target simultaneously — for obesity and other metabolic diseases.

The work will use Generate's platform, which combines generative AI with high-throughput wet-lab experimentation to design proteins. Generate, a Flagship Pioneering-backed biotechnology company that went public earlier in 2026, uses AI-driven technology to develop protein-based medicines.

For the two initial programmes, Generate will receive USD 30 million upfront and up to USD 35 million in early preclinical milestones, and is eligible for total milestones of nearly USD 1.2 billion, including potential development, regulatory, and commercial milestones, plus tiered royalties on future worldwide net sales. The agreement carries an option to add a third programme.

Under the agreement, Generate will lead research through candidate selection, while Zealand will handle clinical development, regulatory submissions and worldwide commercialisation.

The deal broadens Zealand's toolkit beyond its traditional peptide-based medicines and extends Generate's platform into obesity and metabolic disease for the first time. The collaboration will focus on multispecific protein therapies, designed to act on more than one biological target at a time; Zealand has indicated those treatments could target several disease pathways linked to obesity within a single medicine, an approach drugmakers are increasingly exploring as they seek more effective treatments.

For research-procurement teams, the partnership signals that the obesity pipeline's reference compounds within the next decade may include engineered multispecific proteins alongside conventional peptides — a consideration for analytical capability planning and reference standard sourcing.

Novo Nordisk and Nanexa: Reformulating for Monthly and Quarterly Dosing

The third development precedes the Zealand announcements chronologically but remains directly relevant to the October narrative. On 25 September 2026, Novo Nordisk and Swedish drug delivery company Nanexa announced a global exclusive licence and collaboration agreement. The agreement grants Novo a global exclusive licence to Nanexa's PharmaShell atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes, and other cardiometabolic diseases.

PharmaShell applies an inorganic coating to drug particles; coated particles form depots at the injection site and, as the coating dissolves, drug particles enter the bloodstream. The collaboration includes development of long-acting injectable formulations with different administration-frequency profiles, with monthly and quarterly administration as target profiles.

Nanexa has given Novo rights to apply the PharmaShell platform to up to five programmes, with Novo targeting monthly and quarterly administration frequencies.

Financially, EUR 615 million of the total EUR 1.165 billion is tied to upfront consideration and milestones for development and regulatory progress, while the remaining EUR 550 million consists of sales milestones, topped with a low single-digit royalty on global net sales. Neither Novo nor Nanexa has disclosed the size of the initial upfront payment.

Novo has identified the technology as a good fit for plans to differentiate its medicines by extending their dosing windows — a strategic priority made more urgent by the anticipated arrival of oral GLP-1 competitors, including Eli Lilly's orforglipron (recently endorsed by the EMA's CHMP), which remove the injection burden entirely for some patient populations.

Following Nanexa's licence and option agreement with Moderna in 2025, the Novo deal further strengthens external validation of PharmaShell as a broadly applicable drug delivery platform.

What These Three Developments Mean in Aggregate

The simultaneous emergence of clinical evidence for a non-incretin peptide mechanism (amylin), an AI-designed multispecific protein programme, and a depot-forming delivery platform reflects a rational industry response to a maturing GLP-1 market. Each addresses a different limitation of current standard-of-care:

• Mechanism diversity: Petrelintide's amylin pathway complements rather than duplicates GLP-1 signalling, offering potential for combination regimens and for patients who respond poorly to incretin-based therapy.
• Dosing convenience: Monthly or quarterly PharmaShell-enabled injectables would reduce the patient burden of weekly self-injection — relevant to adherence in long-term metabolic disease management.
• Modality expansion: AI-designed multispecific proteins may address combinations of obesity-linked targets that single-receptor peptides cannot reach within a single molecule.

The flurry of deals reflects the broader dynamic: as drugmakers race to develop treatments beyond the blockbuster GLP-1 drugs sold by Novo Nordisk and Eli Lilly, the success of those medicines has fuelled investment across the obesity market, with companies testing approaches aimed at improving effectiveness, convenience, or side-effect profiles.

For UK laboratories involved in translational obesity research or engaged in procurement of peptide research tools, the practical implication is a pipeline diversification that will likely generate demand for a broader set of reference standards and assay panels — including amylin analogues, depot-forming formulations, and, eventually, engineered multispecific proteins — within the medium-term planning horizon.

Sources: Zealand Pharma GlobeNewswire — ZUPREME-2 topline results, 7 October 2026 · Generate Biomedicines / Zealand Pharma GlobeNewswire, 13 October 2026 · Nanexa press release, 24 September 2026 · FierceBiotech — Novo/Nanexa deal, 25 September 2026 · Reuters via KFGO — Zealand/Generate, 13 October 2026 · Pharmacally — petrelintide ZUPREME-2 analysis, 8 October 2026 · Dealroom — Zealand/Generate analysis, October 2026